Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H20FN3O3 |
Molecular Weight | 357.3788 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C[C@@H]2C[C@H]1CN2C3=CC4=C(C=C3F)C(=O)C(=CN4C5CC5)C(O)=O
InChI
InChIKey=QMLVECGLEOSESV-RYUDHWBXSA-N
InChI=1S/C19H20FN3O3/c1-21-7-12-4-11(21)8-22(12)17-6-16-13(5-15(17)20)18(24)14(19(25)26)9-23(16)10-2-3-10/h5-6,9-12H,2-4,7-8H2,1H3,(H,25,26)/t11-,12-/m0/s1
Molecular Formula | C19H20FN3O3 |
Molecular Weight | 357.3788 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2311224 |
|||
Target ID: CHEMBL2311224 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | ADVOCIN Approved UseFor the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica and Pasteurella multocida and for the control of BRD in beef cattle at high risk of developing BRD associated with Mannheimia haemolytica and Pasteurella multocida. Launch Date2011 |
PubMed
Title | Date | PubMed |
---|---|---|
Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration. | 1999 Aug |
|
Pharmacokinetic and pharmacodynamic profiles of danofloxacin administered by two dosing regimens in calves infected with Mannheimia (Pasteurella) haemolytica. | 2002 Sep |
|
Effect of Danofloxacin on Reactive Oxygen Species Production, Lipid Peroxidation and Antioxidant Enzyme Activities in Kidney Tubular Epithelial Cell Line, LLC-PK1. | 2013 Dec |
|
Toxic effects of methylmercury, arsanilic acid and danofloxacin on the differentiation of mouse embryonic stem cells into neural cells. | 2014 |
Patents
Sample Use Guides
Administered by subcutaneous injection at either 8 mg per kilogram of body weight once or 6 mg per kilogram of body weight with treatment repeated
once approximately 48 hours following the first injection.
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:17:14 GMT 2023
by
admin
on
Fri Dec 15 16:17:14 GMT 2023
|
Record UNII |
24CU1YS91D
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 556.169
Created by
admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
|
||
|
CFR |
21 CFR 522.522
Created by
admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
|
||
|
WHO-VATC |
QJ01MA92
Created by
admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
|
||
|
NCI_THESAURUS |
C795
Created by
admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000083438
Created by
admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
|
PRIMARY | |||
|
SUB06901MIG
Created by
admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
|
PRIMARY | |||
|
DB11393
Created by
admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
|
PRIMARY | |||
|
DANOFLOXACIN
Created by
admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
|
PRIMARY | |||
|
112398-08-0
Created by
admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
|
PRIMARY | |||
|
DTXSID0046432
Created by
admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
|
PRIMARY | |||
|
6424
Created by
admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
|
PRIMARY | |||
|
24CU1YS91D
Created by
admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
|
PRIMARY | |||
|
C72731
Created by
admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
|
PRIMARY | |||
|
71335
Created by
admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
|
PRIMARY | |||
|
24CU1YS91D
Created by
admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
|
PRIMARY | |||
|
1358488
Created by
admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
|
PRIMARY | RxNorm | ||
|
m4082
Created by
admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL157548
Created by
admin on Fri Dec 15 16:17:15 GMT 2023 , Edited by admin on Fri Dec 15 16:17:15 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |